←
Metaphore Biotechnologies63 posts
Metaphore Biotechnologies avatar

Metaphore Biotechnologies

@MetaphoreBio

Metaphore is harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.

◷ Joined December 2022▧ 42 Photos and videos
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Nov 9

Last week, the Metaphore team hosted its second annual Science Day to focus on the scientific questions, patient needs, and cross-functional work that will shape what comes next. The program brought together perspectives on the future of antibody discovery and the path toward the clinic. Just as important, it created time for teams across biology, computation, discovery, and development to connect ideas and ask questions. A highlight was hearing from Andy Jablonski, founder of the Short Bowel Syndrome Foundation, Inc., and a person living with short bowel syndrome (SBS). His perspective on living with SBS and his work with the community connected the day’s scientific discussions with the patient experience. We also heard from Andrew Kruse on GPCR signaling and from Tony Manning and Enoch Huang on the questions still ahead in antibody discovery. Thank you to our speakers and everyone at Metaphore who contributed to the day. For more on Metaphore’s approach to designing antibodies that activate, tune, and engage biology, see our new website and animation: metaphorebio.com/science

0:26
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Oct 5

Congratulations to Angela Hwang, CEO of Metaphore Biotechnologies and CEO-Partner at @FlagshipPioneer, on being named to Endpoints News’ 2026 Women in Biopharma list. Angela sets the standard for the company we are building at Metaphore. She asks us to pair bold scientific ambition with disciplined execution, to bring different experiences and perspectives into the room, and to stay accountable for whether our work can make a meaningful difference for patients. That kind of culture does not happen by itself. It requires clear priorities, candid discussion, shared ownership, and leaders who make space for people to contribute their best thinking. Tomorrow, Angela will join the virtual @endpts Women in Biopharma CEO Panel at 11:00 a.m. ET. Register here to watch: events.endpoints.news/womeni… See the full list here: endpoints.news/special-repor…

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Sep 14

“Win Together” is one of Metaphore’s core values, and our team off-site last month gave us a chance to put it into practice beyond the lab. The Metaphore team gathered at the Newton Boathouse for a day of field games, canoeing, friendly competition, and time together. Thank you to everyone who helped make the day possible and brought their energy, teamwork, and competitive spirit.

0:23
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Sep 9

Most antibody medicines are designed to block biology. But many diseases require a different kind of therapeutic action, including activating pathways, tuning signaling, or coordinating activity across multiple targets. In a new interview with Technology Networks, Angela Hwang, Chief Executive Officer of Metaphore Biotechnologies, discusses why expanding what antibodies can be designed to do could open new therapeutic possibilities across disease. She also explains how Metaphore combines large-scale live-cell experimentation, proprietary functional data, and AI/ML to design antibody medicines with unique mechanisms of action from the outset. Read the interview: technologynetworks.com/bioph…

Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Aug 11

A big welcome to Michael Turner, who joins Metaphore as Senior Vice President, Head of Biology and Translational Sciences. He joins us at an important stage as we expand what antibodies can be designed to do. Mike will lead the biology and translational sciences across our programs, helping us identify the right biological opportunities, define what each medicine needs to accomplish, and build the evidence required to advance toward the clinic. He brings more than 20 years of experience spanning inflammation, autoimmune disease, allergy, and immuno-oncology. His leadership will strengthen our ability to turn antibody designs into medicines for diseases where blocking biology is not enough. See how we are designing antibodies to do more: metaphorebio.com/science

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Jul 14

Metaphore is pleased to announce the formation of our Scientific Advisory Board, bringing together leaders across biologics development, protein engineering, AI/ML, immunology, metabolism, and sequence-to-function biology. Across medicine, many diseases require more than blocking biology. Metaphore is building a platform to make new antibody actions designable, creating medicines with unique mechanisms of action. With this, we can unlock a wider therapeutic landscape, enabling new treatment possibilities for millions of patients. Welcome to Tony Manning PhD, Morris Birnbaum, Enoch Huang, Ben Lehner, and Peter Tessier. We look forward to working with this outstanding group as we continue building a new era of antibody medicine. Read the press release for more: metaphorebio.com/news/metaph…

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Jun 23

We've spent decades finding antibodies that bind and hoping some deliver the right therapeutic effect. The next frontier is designing antibodies with therapeutic effect and function from the beginning. Hear CEO Angela Hwang discuss Metaphore’s approach on The Bio Report Podcast.

Most antibodies act as antagonists—but biology isn’t that simple. @MetaphoreBio's function-first platform uses live-cell data + ML to design antibodies that agonize, bias, or multi-target pathways. CEO Angela Hwang explains: thebioreport.podbean.com/e/r…

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·May 18

At Bio-IT World, Metaphore’s Adam Kraut will share how we are building the data architecture behind function-first antibody design, connecting cloud-orchestrated labs, high-throughput functional and multi-omic datasets, and governed cloud infrastructure to support AI/ML and antibody design at scale. Metaphore’s platform starts with measuring function in living systems, generating biological activity data, learning the features that drive function, and designing antibodies with new mechanisms from the outset. That is the next frontier for antibody-based medicines: designing them to activate, bias, and combine biology with intent. Learn more about how Metaphore designs antibodies with new functions: metaphorebio.com/

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·May 14

Metaphore was at PEGS Boston, where our team shared new work at the intersection of antibody engineering, functional data generation, and mechanism design. Today, most antibodies are built to block biology. Metaphore is designing antibodies for new actions, including activating, tuning, and combining, to create functional antibodies with expanded capabilities from the start. Across our posters, we highlighted how this approach comes to life through high-throughput experimental workflows, multi-target antibody discovery, iterative ML-guided design, and library-scale affinity measurement. Learn more about how Metaphore designs antibodies with new functions: metaphorebio.com/

0:15
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Apr 29

We’re excited that Metaphore will host a fellow under A*STAR’s International Fellowship (Innovation) program as part of the broader collaboration between @astar_research and @FlagshipPioneer. At Metaphore, we are building antibody medicines from a different starting point: biological function as it happens in living systems. By combining large-scale live-cell experimentation and machine learning, we are creating a function-first approach to antibody design that moves beyond blocking, and toward medicines that can activate, bias, modulate, and coordinate biology. This could open entirely new categories of antibody-based medicines, expanding one of pharma’s most important drug classes into diseases and mechanisms that conventional approaches have struggled to reach. The role, Chief of Staff to Metaphore’s Chief Scientific Officer offers a postdoctoral fellow the opportunity to work close to the science, strategy, and company building behind this new frontier in antibody medicine. Learn more: a-star.edu.sg/scholarships/h…

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Apr 27

Metaphore is presenting at the 5th Annual GPCRs-Targeted Drug Discovery Summit in Boston, highlighting a new frontier in GPCR antibody discovery: engineering agonism. GPCRs are central to human biology, but have historically been difficult to drug with antibodies because function depends on dynamic receptor states, signaling context, and more than binding alone. Metaphore’s function-first platform is built to design biologics around what they do in living systems. This presentation will highlight how this approach can be applied to GPCRs, including state-specific conformations, antibody-based agonism, signaling bias, and full-molecule engineering for PK, delivery, and developability.

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Apr 23

Metaphore CEO Angela Hwang joined BMO’s 2026 Metabolic Health Summit in New York for a panel on emerging technologies shaping the future of metabolic health. Angela shared Metaphore’s perspective on designing medicines around biological function, not just binding, and how that results in highly differentiated antibodies that can raise the standard of care in metabolic disease. That means applying our function-first platform to create biologics intended to activate, bias, and modulate biology in ways conventional approaches often cannot. Thank you to BMO Capital Markets for convening leaders across biotech, healthcare, and investment to discuss the evolving obesity landscape and its growing relevance across broader cardiometabolic disease.

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Apr 14

Please join us in welcoming Paul Weinreb, Senior Vice President, Biotherapeutics & Enabling Technologies, and Tiffany Chen, Vice President, Head of Operations & Portfolio Strategy, to Metaphore Biotechnologies. Paul brings decades of experience across biologics discovery, molecular engineering, and therapeutic development. Tiffany adds a strong track record in portfolio planning, cross-functional leadership, and operational execution across biotech R&D. Metaphore is advancing a new approach to antibody drug design, bringing together large-scale live-cell experimentation and machine learning to create medicines shaped by biological function. As the company continues to grow, Paul and Tiffany will play important roles in strengthening our platform, portfolio, and path forward. Welcome, Paul and Tiffany!

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Feb 11

This International Day of Women and Girls in Science, we asked our Chief Scientific Officer, Anabella Villalobos for her advice to those building a career in science. Over her 30-year career, Anabella has built a reputation for developing innovative therapeutics across modalities and disease areas, while bringing out the best in people and building strong, collaborative teams. At Metaphore, she helps shape a scientific culture where people are encouraged to speak up, challenge ideas, and contribute fully. Here are three pieces of advice she shared with us for #IDWGS: 1. Raise your hand and be ready to tell your story. 2. Ask for what you want. 3. Seek out mentors and sponsors who will advocate for you. #WomenInScience #WomenInSTEM

0:29
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Feb 9

Taking a brief detour from winter and lab coats. 🌴☀️ A welcome break from the cold, Metaphore’s Hawaiian-themed happy hour was a reminder that good science also needs good company, and occasionally a little sunshine (even if it’s just vibes).

Post attachment
Metaphore Biotechnologies avatar
Metaphore Biotechnologies@MetaphoreBio·Jan 21

What if antibody design started with how biology functions in living systems, not static structure? In this CEO Chat at the @FlagshipPioneer studio at the JP Morgan Healthcare Conference, Angela Hwang walks through why static, structure-first approaches miss critical biological context and how Metaphore captures protein behavior in living systems to design antibodies that activate, tune signaling, and engage multiple targets. This shift to function-first antibodies defines the next frontier in biologics. Watch this short video to learn more, youtube.com/watch?v=NEDjEZ3o… #FlagshipFounded #JPM26 #CEOChat #BiggerLeaps #FlagshipStudio

This week, leaders of #FlagshipFounded companies shared how they’re building differentiated platforms and advancing next-generation medicines. Watch their CEO Chats from the #FlagshipStudio during #JPM26: youtube.com/playlist?list=PL… 🔹 Craig Williams, @AprioriBio 🔹 Ad Rawcliffe, @etiome 🔹 Ajit Singh, @HarbingerHlth 🔹 Angela Hwang, @MetaphoreBio

Post attachmentPost attachmentPost attachmentPost attachment